IsoRay up 24% on heavy volume

Shares of nano cap biotech IsoRay (ISR) continue their up move that began with an opening gap on January 7 when the firm reported the FDA approval of its liquid cesium Cesitrex.

Today's recent price of $1.36 represents a 147% gain from the January 7 close of $0.55.

Investors should exercise caution here considering ISR's market cap of $43M and miniscule sales of $1M/qtr (2013/2012 revenues declined ~7%).

The company executed a public offering in May. The sole book runner was Maxim Group LLC.

A bullish article was published on March 14 at 11:47 am. At precisely the same time, buy orders were placed for ~136,000 shares at $0.84 - $0.89.

10 mutual funds have positions, up from 9 a year earlier.

Comments (5)
  • mystical44
    , contributor
    Comments (36) | Send Message
    Agreed. That article was highly suspicious and the author likely had skin in the game, but ISR is a highly undervalued company regardless of the authors selfish intentions.

    19 Mar 2014, 01:15 PM Reply Like
  • Hoang6
    , contributor
    Comments (358) | Send Message
    I also think it's time for ISR to receive the recognition, very undervalued. Anyone think it's a buyout target?
    19 Mar 2014, 01:53 PM Reply Like
  • yworry
    , contributor
    Comments (30) | Send Message
    ISR is undervalued at even $3 especially when you consider that there are companies with 0 FDA approvals and drugs in the market trading at a higher pps. Plus ISR has a monopoly in seed brachytherapy and medical radioisotope applications. What got everyone's attention was when they announced(3/19) the world’s first pediatric cesium-131 seeded mesh treatment for metastatic wilms tumor. This should hopefully give ISR much needed publicity and help attract additional investors.
    19 Mar 2014, 03:24 PM Reply Like
  • beefreetwo
    , contributor
    Comments (2) | Send Message
    I got lucky after someone pointed out this stock yesterday and seeking alpha had a comment that's said isr was worth 3.00 so I bought in a nice amount at 1.05 yesterday an I made a bunch.sold 1/2 an think it short term it will run up.But I will take more profits along the way.
    19 Mar 2014, 08:49 PM Reply Like
  • Hoang6
    , contributor
    Comments (358) | Send Message
    With a market cap of 110M, it still has plenty of room to grow. There are many small caps out worth several times that of ISR without a single approved drug. Once ISR gets the attention, the future is bright.
    20 Mar 2014, 12:50 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs